News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEvents
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Amanda McKaig, BSN, RN, OCN

Advertisement

Articles by Amanda McKaig, BSN, RN, OCN

Alyssa Ridad

Ridad and McKaig Discuss Oncology Nurse Perceptions on Medical Cannabis

ByAlyssa Ridad, BSN-RN, OCN,Amanda McKaig, BSN, RN, OCN
May 30th 2023

Alyssa Ridad BSN-RN, OCN; and Amanda McKaig, BSN, RN, OCN, discuss oncology nurse perceptions of medical cannabis.

Advertisement

Latest Updated Articles

  • Alyssa Ridad
    Ridad and McKaig Discuss Oncology Nurse Perceptions on Medical Cannabis

    Published: May 30th 2023 | Updated:



Advertisement
Advertisement

Trending on Oncology Nursing News

1

FDA Greenlights Niraparib/Abiraterone Acetate With Prednisone in mHSPC

2

Oral Azacitidine Yields Similar PK to Subcutaneous Azacitidine in MDS/CMML

3

Frontline Axi-Cel CR Linked With Improved Survival in High-Risk LBCL

4

Dexamethasone Reduces ICANS Severity in Axi-Cel in LBCL

5

Teclistamab/Daratumumab Increases OS, PFS in R/R Multiple Myeloma

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us